Table 2 Characteristics of patients who discontinued radiotherapy
No | Age (years)/Gender | Smoking history (pack-years) | Pathological type/Tumor stage | Treatment modality | Induction chemotherapy regimen | Radiotherapy dose (Gy/fraction) | Percentage of lung volume affected in subclinical ILD (%) | Grade of RP |
|---|---|---|---|---|---|---|---|---|
1 | 68/Male | 40 | Squamous cell carcinoma/IIIB | RT | Cisplatin + gemcitabine | 44.0/22 | ≥ 25 | 4 |
2 | 77/Male | 50 | Squamous cell carcinoma/IIIB | RT | Carboplatin + gemcitabine | 49.5/22 | ≥ 25 | 5 |
3 | 67/Male | No | Squamous cell carcinoma/postoperative stump recurrence | RT | Cisplatin + gemcitabine | 24.0/12 | < 25 | 2 |
4 | 63/Male | 80 | Adenocarcinoma/IIIB | RT | Cisplatin + gemcitabine | 58.0/29 | < 25 | 3 |
5 | 65/Male | 40 | NSCLC/IIIB | RT | Cisplatin + vinorelbine | 38.0/19 | < 25 | 4 |
6 | 69/Male | 50 | Squamous cell carcinoma/IIIB | RT | Carboplatin + gemcitabine | 38.0/19 | ≥ 25 | 5 |
7 | 52/Male | 60 | Adenocarcinoma/IIIB | RT | Cisplatin + pemetrexed | 30.0/15 | < 25 | 2 |
8 | 67/Male | No | SCLC/IIIB | RT | Carboplatin + etoposide | 40.0/20 | < 25 | 2 |